aHUS Trial Watch 15 (Iptacopan)
Iptacopan is a complement inhibitor that it is taken orally, twice daily. It works by inhibiting Complement Factor B (CFB ).…
aHUS are we there yet?
Last summer, aHUS alliance’s Twitter Account featured the plight of a patient who, after a week in hospital, had been found…
Advocacy punching above its aHUS weight
There is so much chat these days about what things should be like after the pandemic. Though it does seem at…
TÜRKİYE’DE Kİ; aHÜS H; ASTALIĞINA GENEL BİR BAKIŞ!
Atipik Hemolitik Üremik Sendrom kısaca aHÜS, vücudumuzun bağışıklık sisteminin ana elemanlarından olan ana savunma sisteminin de ki bir parçanın regülasyon bozukluğu…
COVID and aHUS at the end of 2021
As the year ends we are still living with COVID. It seems like it is never ending. And it is and…
aHUS Diagnosis Process – Report 2
The second article in the series about the aHUS Diagnosis Process has been published on the website today. Research made possible…
aHUS Trial Watch 14
A trial has been designed by Alexion to examine the efficacy of Ravulizumab to treat those with a Thrombotic Microngiopathy ,…
One genetic problem but two diseases
Take "diacylglycerol kinase " and add a "syndrome" throw in a letter from the Greek alphabet " ε" and you have…
Living with aHUS- what would you say?
If asked by health policy decision makers, and with a 500 words limit, how would you answer the question "how does…